NCT06644625Recruiting
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
Source: ClinicalTrials.gov · Last updated 13 Jul 2026
Brief summary (registry, in English)
The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and improve long term outcomes.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1665 (estimated)
- First submitted
- 27 Sept 2024
- Start date
- 1 Mar 2025
- Primary completion date
- 31 Jan 2035
- Lead sponsor
- Wake Forest University Health Sciences
- Diseases
- Multiple myeloma
- NCT number
- NCT06644625
What you commit to
- Study type: Observational
- Planned participants: 1665
- From 1 Mar 2025 to the primary completion date, 31 Jan 2035
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- SCREENING Inclusion Criteria:
- Age 30 years or older at the time of consent
- Either:
- Self-identify as Black and/or African American OR
- First-degree relatives (parents, siblings, or children) of patients of any race or ethnicity diagnosed with a plasma cell disorder, including MGUS, smoldering multiple myeloma (SMM), multiple myeloma (MM), solitary plasmacytoma, plasma cell leukemia, AL amyloidosis, POEMS syndrome, and Waldenström's Macroglobulinemia
- Capable and willing to provide informed consent. NOTE: HIPAA (Health Insurance Portability and Accountability Act) authorization for the release of personal health information may be included in the informed consent or obtained separately
- Reside in Charlotte, NC, or the surrounding area, based on self-report
- SCREENING Exclusion Criteria:
- Self-reported history of MGUS, SMM, MM, AL amyloidosis, plasma cell leukemia, solitary plasmacytoma, Waldenstrom Macroglobulinemia, and POEMS.
- LONGITUDINAL Inclusion Criteria:
- Test positive for monoclonal gammopathy during screening portion of the study
- Consent to the longitudinal portion of the study
- LONGITUDINAL Exclusion Criteria:
- The participant previously underwent diagnostic work up as part of CHAAMP Internal Pilot that did not result in a diagnosis of MGUS, Smoldering Multiple Myeloma or other non-plasma cell disorder.
Age in the registry: 30 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Atrium Health Levine Cancer Coordinator of this site? Confirm its status | Charlotte | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.